Cochrane · systematic review · CD007986

Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents

Gillies, D, Leach, MJ, Perez Algorta, G · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 2 · 33.3%High 3 · 50%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Summary of findings table ‐ PUFA compared to placebo for children and adolescents with ADHD

Population: children and adolescents with ADHD
6 questions
OutcomeEffectEvidenceStatus / GRADE
ADHD symptoms – improvement – medium term
Summary of findings table ‐ PUFA vs placebo
RR 1.95 [1.47, 2.6]3 studies · 191 participantsLow
Downgraded: risk of bias, imprecision
ADHD symptoms – total, parent‐rated – medium term
Summary of findings table ‐ PUFA vs placebo
no estimate extracted16 studies · 1166 participantsHigh
ADHD symptoms – inattention, parent‐rated – medium term
Summary of findings table ‐ PUFA vs placebo
no estimate extracted12 studies · 960 participantsHigh
ADHD symptoms – hyperactivity/impulsivity, parent‐rated – medium term
Summary of findings table ‐ PUFA vs placebo
no estimate extracted10 studies · 869 participantsHigh
Side effects – overall
Summary of findings table ‐ PUFA vs placebo
RR 1.02 [0.69, 1.52]8 studies · 591 participantsModerate
Downgraded: imprecision
Loss to
Summary of findings table ‐ PUFA vs placebo
RR 1.03 [0.77, 1.37]13 studies · 1121 participantsModerate
Downgraded: imprecision